The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024IND-enabling Studies of a Molecule that Enhances Mitophagy as Disease-modifying Therapy for Parkinson's Disease
Study Rationale: Studies show that Parkinson's disease (PD) is frequently associated with damage to mitochondria, structures that provide cells with the energy they need to function. In particular, a...
-
2021 RFA: PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development, 2024SUPPLEMENT: Rescreening of the MJFF Compound Library to Identify Molecules that Can be Used to Monitor Alpha-synuclein
Study Rationale: Alpha-synuclein is a key protein involved in the pathology of Parkinson’s disease (PD). We recently confirmed that two compounds developed under the MJFF Alpha-synuclein Imaging...
-
ASAP CRN Competitive Renewal Opportunity, 2024Mapping the Modulatory Landscape Governing Dopamine-acetylcholine Signaling and its Dysregulation in Parkinson’s Disease
Study Rationale: In people with Parkinson's disease (PD), nerve cells that make and release the chemical dopamine start to die. This loss affects the striatum, a brain region that normally receives...
-
ASAP CRN Competitive Renewal Opportunity, 2024Determining the Role of Proteins Associated with Parkinson’s Disease in T cell-Mediated Destruction of Dopamine Neurons
Study Rationale: Before Parkinson's disease (PD) manifests its characteristic symptoms, the pathological process has been underway for years. Although the initial trigger remains uncertain, we have...
-
ASAP CRN Competitive Renewal Opportunity, 2024Identifying Mechanisms that Overwhelm Protein and Organelle Quality Control in Parkinson’s Disease
Study Rationale: Abnormal protein aggregation and prion-like aggregate spreading are hallmarks of the degenerative cascades of sporadic and familial Parkinson’s disease (PD). These toxic aggregates...
-
ASAP CRN Competitive Renewal Opportunity, 2024IMPACT-PD: Implications of Polyamine and Glucosylceramide Transport in Parkinson’s Disease
Study Rationale: Mutations in the genes ATP13A2, GBA1 and ATP10B trigger Parkinson’s disease (PD) and cause dysfunction of lysosomes, the recycling compartments of the cell. These genes regulate the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.